News: Prostate Cancer

Next Page »

New options enhance prostate cancer treatment

Thursday, January 29th, 2015

Vanderbilt-Ingram Cancer Center (VICC) patient William Ostman smiled while gazing into a camera lens and declared, “I am a prostate cancer survivor.” Ostman, 63, who now lives in Hermitage, Tennessee, was sharing his story recently in a video for the nonprofit organization ZERO – The End of Prostate Cancer. The fact that he is still […]

Potential Prostate Cancer Blood Test

Tuesday, January 6th, 2015

Vanderbilt University researcher William Mitchell, M.D., Ph.D., and colleagues in Germany and Canada have demonstrated a method for detecting “cell-free” tumor DNA in the bloodstream.

Key to Prostate Cancer Resistance

Friday, October 31st, 2014

Findings suggest a combination of therapies that may be effective in treating resistant prostate cancers

Prostate Cancer Study of Long-term Effects

Thursday, January 31st, 2013

A new study comparing outcomes among prostate cancer patients treated with surgery versus radiotherapy found differences in urinary, bowel and sexual function after short-term follow-up, but those differences were no longer significant 15 years after initial treatment. The study, led by first author Matthew Resnick, M.D., instructor in Urologic Surgery, Vanderbilt University Medical Center, was […]

Gene Linked to Familial Prostate Cancer

Tuesday, August 28th, 2012

Family history is the best predictor of risk for prostate cancer, suggesting that the disease has a strong hereditary component. Recently, a heritable mutation in the HOXB13 gene was found to predispose men of European descent to prostate cancer. Jeffrey Smith, M.D., Ph.D., associate professor of Medicine and Cancer Biology, and colleagues initiated a study […]

Study Reveals Racial Disparities in Prostate Cancer Care

Thursday, August 23rd, 2012

A study led by investigators from Vanderbilt-Ingram Cancer Center (VICC), Nashville, Tenn., finds that black men with prostate cancer receive lower quality surgical care than white men. The racial differences persist even when controlling for factors such as the year of surgery, age, comorbidities and insurance status. Daniel Barocas, M.D., MPH, assistant professor of Urologic […]

Proteins May Point to Prostate Cancer Drug Targets

Tuesday, August 7th, 2012

Two proteins that act in opposing directions – one that promotes cancer and one that suppresses cancer — regulate the same set of genes in prostate cancer, Vanderbilt-Ingram Cancer Center researchers have found. The findings, reported recently in the Journal of Clinical Investigation, point toward potential drug targets and prognostic markers for prostate cancer. “We […]

Proteins Guard Against Cancer Spread

Thursday, July 26th, 2012

Prostate cancer cells metastasize mainly to bone, yet bone metastases are resistant to common therapies and are often fatal. A key receptor for the growth factor TGF-β (TβRII) is lost in the connective tissue (stroma) of most prostate cancers, but the effects of this loss on metastasis and bone lesion development are undefined. Recently in […]

VICC to Host NCCN 2012 Congress Series

Wednesday, July 11th, 2012

Earn up to 5.5 continuing education credits! Program Overview: This congress is a full-day educational program designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Bladder, Kidney, and Prostate Cancers. Participants will learn how to implement the NCCN Guidelines recommendations into their […]

Going for the Gold

Tuesday, April 17th, 2012

Vanderbilt-Ingram Cancer Center cordially invites you and your guests to join us for Going for the Gold: Living Well through Cancer! Due to an overwhelming response, we have closed registration. We are thrilled to have so many people attend! Date: Saturday, June 30, 2012 Time: 9:30 a.m.-2:30 p.m. Where: Vanderbilt University Student Life Center 310 […]